TISSIUM is a privately-owned life science company developing fully synthetic, biomorphic programmable polymers.
TISSIUM is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.
TISSIUM was founded in 2013 by Christophe Bancel, & Maria Pereira. The company is headquartered in Paris, Paris, France, with an office in Boston, Massachusetts.
TISSIUM address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.
TISSIUM's unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
TISSIUM's platform is based on a proprietary polymer family with unique properties including the ability to conform to, and integrate with, surrounding tissue to enable natural healing. Furthermore, the modular design of the polymers enables customization to match tissue-specific requirements for different therapeutic areas. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.
TISSIUM is backed by Bpifrance, BNP Paribas Développement, European Investment Fund (EIF), M&L Investments, ValQuest Partners and others. The company raised €38.75M ($42.78M) from a "Series B" financing on Nov 20, 2019. This new round brings TISSIUM's total funding to $86.15M €77.95M) to date.